Compare VABK & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VABK | MDXH |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.8M | 183.4M |
| IPO Year | 2013 | 2021 |
| Metric | VABK | MDXH |
|---|---|---|
| Price | $38.36 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 11.0K | ★ 102.2K |
| Earning Date | 04-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $15.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.56 | $1.36 |
| 52 Week High | $44.50 | $5.33 |
| Indicator | VABK | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 38.45 |
| Support Level | $37.01 | $3.05 |
| Resistance Level | $41.33 | $3.78 |
| Average True Range (ATR) | 0.93 | 0.14 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 42.26 | 11.49 |
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.